Posted on 5 月 15, 20255/15/25
From Science to Value: Strategic Asset Valuation for Biotech Licensing and Fundraising
Posted on 5 月 1, 20255/1/25
Maximizing Medical Affairs and MSL Impact: How Choosing a Strategic Launch Partner Propels Success
Posted on 4 月 11, 20254/11/25
Unlocking Pharma Success: Mike Ryan’s Pre-Conference Talk at Reuters Pharma 2025
Posted on 4 月 1, 20254/1/25
Escaping the Chronic Microcap Trap: How Launching Alone Is the Only Option for Growth
Posted on 2 月 21, 20252/21/25
Transformative Commercialization for New Biopharma Entrants: Ensuring Success With Capital and Time Efficiency
Posted on 11 月 27, 202411/27/24
From Challenges to Solutions: Breaking Barriers to Revolutionize Patient Services
Posted on 9 月 23, 20249/23/24
Launching in the EU/U.K.: The 7-Step Countdown to Success
Posted on 9 月 5, 20249/5/24
The Promise of a Direct-to-Patient Model – Breaking Down What’s Really Needed for Better Patient Access
Posted on 8 月 5, 20248/5/24
Understanding IDNs and What They Mean to the Pharmaceutical Industry–Q&A with Greg Skalicky
Posted on 6 月 28, 20246/28/24